Inovio Launches Underwritten Stock Offering Days After First FDA Approval
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio filed a preliminary prospectus for an underwritten common stock offering led by Jefferies and Piper Sandler, days after FDA approval of VOCERYQ and while carrying a going-concern warning. Terms and size are not yet set.
Key Events · Financing and Capital Events · INO
-
Underwritten Offering Launched
A preliminary prospectus supplement covers an underwritten common stock offering with Jefferies and Piper Sandler as joint book-running managers; the share count and public offering price are left blank.
-
Going-Concern Warning Restated
The filing states that Inovio does not have sufficient working capital to fund planned operations for the next twelve months and that substantial doubt exists about its ability to continue as a going concern.
-
Cash Position and Share Count
Preliminary estimated cash, cash equivalents and short-term investments were approximately $48.4 million as of September 30, 2026, against 110,181,507 shares outstanding as of the same date.
-
Pricing Reference and Lock-Ups
The last reported sale price was $1.62 on November 4, 2026; the company and its officers and directors agreed to 90-day lock-ups, and underwriters hold a 30-day option for additional shares.
Analysis · INO · Life Sciences
Inovio is raising equity just six days after winning FDA accelerated approval for VOCERYQ, its first commercial product. The filing discloses that the company lacks sufficient working capital for the next twelve months and that substantial doubt exists about its ability to continue as a going concern, making this raise survival capital for a launch it has already begun staffing. Because the preliminary prospectus leaves the share count and price blank, the size and dilution are not yet fixed. The last reported sale price was $1.62 on November 4, 2026, against a $1.20 price as of this report, so the deal will be priced into a stock that has already moved. Existing holders should expect dilution on top of roughly 161 million shares of already-outstanding warrants and options, many struck well above the current price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.